Trials / Unknown
UnknownNCT03546855
Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
Clinical Study of Apatinib Mesylate in the Treatment of Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
Detailed description
Eligible patients will receive apatinib treatment until disease progression or intolerable toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib 500mg/d po,28 days as one cycle |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-12-01
- Completion
- 2020-06-01
- First posted
- 2018-06-06
- Last updated
- 2018-06-06
Source: ClinicalTrials.gov record NCT03546855. Inclusion in this directory is not an endorsement.